Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
Active, not recruiting · NCT07020377 · Registry updated 2025-06-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM). | Digestive System Diseases, Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | Active, not recruiting | Phase 1 / Phase 2 | 2025-06-13 | NCT07020377 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alexandria University | 113 |
| Amira Bisher,PhD | 1 |
| Egyptian Liver Hospital | 1 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Alexandria university main hospital | Alexandria | Egypt | 1 |
| Egyptian liver hospital | Al Mansurah | Egypt | 1 |